Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...

Blinding

Blinding

Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.

Drug Administration and Therapy Phases: Overview

Drug Administration and Therapy Phases: Overview

Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...

Clinical Trials

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...

Clinical Trials: Overview

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Long-term safety and tolerability of bimagrumab (BYM338) in sporadic inclusion body myositis.

Neurology·2020

Same author

Improvement of distal acquired demyelinating symmetric (DADS) neuropathy after exposure to factor Xa inhibitor.

Journal of the neurological sciences·2018

Same author

Ethical Issues in the Neurology of Pregnancy.

Seminars in neurology·2017

Same author

Ethics of Preclinical Dopamine Transporter Imaging.

Continuum (Minneapolis, Minn.)·2016

Same author

Withdrawing and withholding life-sustaining treatment.

Handbook of clinical neurology·2013

Same author

Variability in the Perception of Informed Consent for IV-tPA during Telestroke Consultation.

Frontiers in neurology·2012

Same journal

Associations of neuropathic pain and pain catastrophizing with rehabilitation outcomes in patients with stroke.

Topics in stroke rehabilitation·2026

Same journal

Education level amplifies the mediating pathway of rehabilitation motivation between metacognition and quality of life in stroke survivors.

Topics in stroke rehabilitation·2026

Same journal

Cortical activation and functional connectivity during thumb-to-finger opposition in patients with stroke with varying functional levels: insights from fNIRS.

Topics in stroke rehabilitation·2026

Same journal

Cognitive strategies for improving activity-level outcomes post stroke: an integrative review.

Topics in stroke rehabilitation·2026

Same journal

Efficacy of repetitive transcranial magnetic stimulation combined with soft robotic glove training for slight-to-moderate post-stroke upper limb spasticity: a randomized controlled trial.

Topics in stroke rehabilitation·2026

Same journal

Common coping and collaborative management of stroke survivors' spousal caregivers: a moderated mediation model of illness perception and resilience.

Topics in stroke rehabilitation·2026

See all related articles

Search research articles

Related Experiment Video

Updated: May 14, 2026

Remotely Supervised Transcranial Direct Current Stimulation: An Update on Safety and Tolerability

Remotely Supervised Transcranial Direct Current Stimulation: An Update on Safety and Tolerability

Published on: October 7, 2017

Off-protocol access to study therapies.

Thomas I Cochrane¹

¹Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA.

Topics in Stroke Rehabilitation

|January 24, 2013

Summary

This summary is machine-generated.

Researchers explored the ethics of off-protocol access to study therapies like recombinant factor VIIa for intracerebral hemorrhage. This therapy was later found ineffective, raising questions about patient consent and trial integrity.

More Related Videos

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation (tDCS) in Multiple Sclerosis (MS)

A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation (tDCS) in Multiple Sclerosis (MS)

Published on: December 26, 2015

Related Experiment Videos

Last Updated: May 14, 2026

Remotely Supervised Transcranial Direct Current Stimulation: An Update on Safety and Tolerability

Remotely Supervised Transcranial Direct Current Stimulation: An Update on Safety and Tolerability

Published on: October 7, 2017

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation (tDCS) in Multiple Sclerosis (MS)

A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation (tDCS) in Multiple Sclerosis (MS)

Published on: December 26, 2015

Area of Science:

Clinical Ethics
Neurology
Pharmacology

Background:

Ethical considerations arise regarding patient access to investigational therapies outside of clinical trial protocols.
Recombinant factor VIIa (rVIIa) was studied for treating intracerebral hemorrhage, a condition with high mortality and morbidity.
Clinical trials necessitate rigorous adherence to protocols to ensure data integrity and patient safety.

Observation:

Researchers faced ethical dilemmas concerning off-protocol administration of rVIIa to critically ill patients with intracerebral hemorrhage.
The equipoise principle, questioning patient indifference between treatment and placebo, was a central ethical challenge.
The potential for perceived benefit, even if later disproven, complicated decisions about treatment allocation.

Findings:

Recombinant factor VIIa was ultimately found to be ineffective for treating intracerebral hemorrhage.
The ethical debate centered on whether patients could provide informed consent when uncertain about treatment efficacy.
The struggle to balance patient well-being with the need for unbiased trial data was significant.

Implications:

The findings highlight the complexities of ethical decision-making in clinical research, particularly with critically ill populations.
Clear guidelines are needed for managing off-protocol requests and ensuring patient-centered care within research.
This case underscores the importance of ongoing ethical review and adaptation in response to emerging scientific evidence.